ADMA Biologics (ADMA) risk factors

Item 1A of every ADMA Biologics, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.

Open ADMA in Gloom →

ADMA Biologics' chart, financials and news, free in your browser.Open ADMA in Gloom →

FY2025 10-K risk factors
54 risks3 new1 dropped18 reworded
Refinancing replaced Ares credit facilities with a larger $300 million JPMorgan credit agreement. AI adoption introduced new operational and reputational risks regarding ADMAlytics. Regulatory and legal uncertainties grew following 2025 federal changes and Supreme Court rulings.
Filed Feb 25, 2026
FY2024 10-K risk factors
52 risks
Risk factors are dominated by profitability maintenance after achieving first GAAP net income in 2024. Heavy reliance exists on key customers and single-source manufacturing. Regulatory compliance for plasma products and IP protection drive operational risks.
Filed Mar 18, 2025